Novel Anticoagulants for VTE Treatment: The Future of Antithrombotic Therapy
Venous thromboembolism (VTE), encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE), presents a significant global health challenge, affecting millions of individuals annually.
DVT occurs when a blood clot forms in a deep vein, typically in the legs, while PE arises when such a clot dislodges and travels to the lungs, causing potentially life-threatening complications.
The increasing prevalence of VTE, driven by factors such as aging populations, sedentary lifestyles, and rising incidences of chronic diseases, underscores the urgent need for effective treatment strategies.
The VTE treatment market is characterized by a dynamic landscape, with continuous advancements in pharmacotherapy playing a central role.